Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.52 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.52 |
| ▸ | SMOX | Q9NWM0 | 2/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16995671 | 0.90 | KDM1A (0.48) | KDM1ARCOR1SMOXDPP4LMNA | |
| SCHEMBL16995714 | 0.90 | KDM1A (0.64) | KDM1ARCOR1SMOXDPP4LMNA | |
| SCHEMBL16995690 | 0.89 | KDM1A (0.50) | KDM1ARCOR1SMOXDPP4LMNA | |
| SCHEMBL16995663 | 0.88 | KDM1A (0.49) | KDM1ARCOR1SMOXDPP4LMNA | |
| SCHEMBL16995660 | 0.86 | KDM1A (0.49) | KDM1ARCOR1SMOXDPP4LMNA | |
| SCHEMBL16995661 | 0.85 | KDM1A (0.48) | KDM1ARCOR1SMOXDPP4LMNA | |
| SCHEMBL16995719 | 0.85 | KDM1A (0.48) | KDM1ARCOR1SMOXLMNAMAPT | |
| SCHEMBL16995666 | 0.85 | KDM1A (0.48) | KDM1ARCOR1SMOXDPP4LMNA | |
| SCHEMBL18359066 | 0.85 | KDM1A (0.48) | KDM1ARCOR1SMOXDPP4LMNA | |
| SCHEMBL16995681 | 0.84 | KDM1A (0.50) | KDM1ARCOR1SMOXDPP4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015120281-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | KDM1A, KDM1B, KDM3A | KDM1A 1/4885RCOR1 488/4885SMOX 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.